Results 241 to 250 of about 351,954 (346)

LncRNA H19‐Encoded Micropeptide altH19 Promotes DNA Replication and Mitosis in Myeloma Cells by Enhancing the Phosphorylation of CDK2 at Threonine 160

Cell Proliferation, EarlyView.
The micropeptide altH19 interacts with phosphorylated CDK2 (p‐CDK2), subsequently activating CDK2 phosphorylation. This enhances the downstream E2F1 target gene RB activity, which accelerates DNA replication, ultimately leading to rapid myeloma cell mitosis and proliferation.
Yaxin Zhang, Wenjing Li, Xu Cao, Jiwei Mao, Xiaodan Zhou, Linlin Liu, Ruosi Yao   +6 more
wiley   +1 more source

Molecular and immunological determinants of long-term survival in multiple myeloma. [PDF]

Blood Adv
Kasomva K, Yadav K, Janz S, Dhakal B, Rao S.   +4 more
europepmc   +1 more source

Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]

, 2019
al., et, Vij, Ravi
core   +1 more source

Evaluation of response to arsenic trioxide in patients with refractory multiple myeloma

, 2010
Zohreh Sanaat, M Rezazadeh, J Vaez Gharamaleki, J Eyvazi Ziaei, Ali Esfahani, Morteza Ghojazadeh   +5 more
openalex   +1 more source

Supplementary Tables from CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression [PDF]

Jingya Wang, Ziyi Peng, Jing Guo, Yixuan Wang, Sheng Wang, Hongmei Jiang, Mengqi Wang, Ying Xie, Xin Li, Meilin Hu, Yangyang Xie, Hao Cheng, Tiantian Li, Linchuang Jia, Jia Song, Yafei Wang, Jian Hou, Zhi-Qiang Liu   +17 more
openalex   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide

Blood Cancer Journal
Diana Cirstea, Rajib Shome, Mehmet Samur, Srikanth Talluri, Joseph J. Connolly, Alexandra Jean Wright, Emilie Duvallet, Amanda N. R. Joyce, Kathleen Lively, Gina Basinsky, Andrew J. Yee, Cristiana Costa Chase, Ehsan Malek, Ruben Niesvizky, Paul G. Richardson, Noopur S. Raje   +15 more
doaj   +1 more source

Reversal of MPPa‐PDT Resistance in Osteosarcoma by Targeting ROCK2‐Mediated Autophagy

Cell Proliferation, EarlyView.
ROCK2 competes with MST1 to bind to the aa 28‐198 region of SAV1 and then regulates the Hippo pathway to affect autophagy, resulting in the resistance of OS to MPPa‐PDT. Targeted inhibition of ROCK2 by screening for J059‐0149 increases the sensitivity of osteosarcoma to MPPa‐PDT. ABSTRACT Osteosarcoma (OS) is a primary bone tumour that occurs mostly in
Xuan Yi, Xueqiang Deng, Jianyong Deng, Chen Li, Hong Peng, Yunyan Du, Qing Li, Xiaohua Yan, Xin Hu, Yan Zheng, Shenliang Chen, Ting Xiong, Debin Xu, Leifeng Chen, Liang Hao   +14 more
wiley   +1 more source

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Cancer Biology & Medicine
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao, Zhen Cai   +8 more
doaj   +1 more source

Outcomes of relapse after teclistamab therapy in multiple myeloma. [PDF]

Blood Cancer J
Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali ZS, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S.   +14 more
europepmc   +1 more source